Dr. Drake is a Professor in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina and SmartState Endowed Chair in Proteomics. He is an experienced protein biochemist and glycobiologist, with particular expertise in tumor biology and biomarker discovery from clinical fluids and tissues related to urological cancers and other cancers. He obtained his Ph.D. in Biochemistry at the University of Kentucky with Boyd Haley, generating multiple nucleotide sugar photoaffinity analogs for use in the study of glycosyltransferases. More extensive glycobiology training was done in post-doctoral work with Alan Elbein, and he began his academic career in Dr. Elbein’s department at the University of Arkansas for Medical Sciences. Currently, his research focus is on direct analysis of glycans and glycolipids in tissues using state-of-the-art MALDI mass spectrometry imaging approaches. Complementary glycopeptide mass spectrometry and metabolic labeling targeted approaches are being done to identify specific glycoproteins involved in the epithelial-to-mesenchymal transition.

Select Guide Rating

• 1. The Importance of Histology and Pathology in Mass Spectrometry Imaging2. Applications of Mass Spectrometry Imaging to Cancer3. Assessing the Potential of Metal-Assisted Imaging Mass Spectrometry in Cancer Research4. MALDI Mass Spectrometry Imaging of N-Linked Glycans in Cancer Tissues5. In Situ Metabolomics in Cancer by Mass Spectrometry Imaging6. Mass Spectrometry Imaging in Oncology Drug Discovery7. MALDI IMS and Cancer Tissue Microarrays8. Mass Spectrometry Imaging for the Investigation of Intratumor Heterogeneity9. Ambient Mass Spectrometry in Cancer Research10. Rapid Mass Spectrometry Imaging to Assess the Biochemical Profile of Pituitary Tissue for Potential Intraoperative Usage11. Mass Spectrometry Imaging in Cancer Research: Future Perspectives

Dr. Drake is a Professor in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina and SmartState Endowed Chair in Proteomics. He is an experienced protein biochemist and glycobiologist, with particular expertise in tumor biology and biomarker discovery from clinical fluids and tissues related to urological cancers and other cancers. He obtained his Ph.D. in Biochemistry at the University of Kentucky with Boyd Haley, generating multiple nucleotide sugar photoaffinity analogs for use in the study of glycosyltransferases. More extensive glycobiology training was done in post-doctoral work with Alan Elbein, and he began his academic career in Dr. Elbein’s department at the University of Arkansas for Medical Sciences. Currently, his research focus is on direct analysis of glycans and glycolipids in tissues using state-of-the-art MALDI mass spectrometry imaging approaches. Complementary glycopeptide mass spectrometry and metabolic labeling targeted approaches are being done to identify specific glycoproteins involved in the epithelial-to-mesenchymal transition.

Select Guide Rating

• 1. The Importance of Histology and Pathology in Mass Spectrometry Imaging2. Applications of Mass Spectrometry Imaging to Cancer3. Assessing the Potential of Metal-Assisted Imaging Mass Spectrometry in Cancer Research4. MALDI Mass Spectrometry Imaging of N-Linked Glycans in Cancer Tissues5. In Situ Metabolomics in Cancer by Mass Spectrometry Imaging6. Mass Spectrometry Imaging in Oncology Drug Discovery7. MALDI IMS and Cancer Tissue Microarrays8. Mass Spectrometry Imaging for the Investigation of Intratumor Heterogeneity9. Ambient Mass Spectrometry in Cancer Research10. Rapid Mass Spectrometry Imaging to Assess the Biochemical Profile of Pituitary Tissue for Potential Intraoperative Usage11. Mass Spectrometry Imaging in Cancer Research: Future Perspectives

Dr. Drake is a Professor in the Department of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina and SmartState Endowed Chair in Proteomics. He is an experienced protein biochemist and glycobiologist, with particular expertise in tumor biology and biomarker discovery from clinical fluids and tissues related to urological cancers and other cancers. He obtained his Ph.D. in Biochemistry at the University of Kentucky with Boyd Haley, generating multiple nucleotide sugar photoaffinity analogs for use in the study of glycosyltransferases. More extensive glycobiology training was done in post-doctoral work with Alan Elbein, and he began his academic career in Dr. Elbein’s department at the University of Arkansas for Medical Sciences. Currently, his research focus is on direct analysis of glycans and glycolipids in tissues using state-of-the-art MALDI mass spectrometry imaging approaches. Complementary glycopeptide mass spectrometry and metabolic labeling targeted approaches are being done to identify specific glycoproteins involved in the epithelial-to-mesenchymal transition.

Select Guide Rating

• 1. The Importance of Histology and Pathology in Mass Spectrometry Imaging2. Applications of Mass Spectrometry Imaging to Cancer3. Assessing the Potential of Metal-Assisted Imaging Mass Spectrometry in Cancer Research4. MALDI Mass Spectrometry Imaging of N-Linked Glycans in Cancer Tissues5. In Situ Metabolomics in Cancer by Mass Spectrometry Imaging6. Mass Spectrometry Imaging in Oncology Drug Discovery7. MALDI IMS and Cancer Tissue Microarrays8. Mass Spectrometry Imaging for the Investigation of Intratumor Heterogeneity9. Ambient Mass Spectrometry in Cancer Research10. Rapid Mass Spectrometry Imaging to Assess the Biochemical Profile of Pituitary Tissue for Potential Intraoperative Usage11. Mass Spectrometry Imaging in Cancer Research: Future Perspectives